Validation of a Disease-Free Survival Prediction Model Using UBE2C and Clinical Indicators in Breast Cancer Patients

Jun Shen,1,* Huanhuan Yan,1,* Congying Yang,2 Haiyue Lin,2 Fan Li,1 Jun Zhou1 1Department of Breast Surgery, The First People’s Hospital of Lianyungang, The First Affiliated Hospital of Kangda College of Nanjing Medical University, Lianyungang, Jiangsu, 222002, People’s Republic of C...

Full description

Bibliographic Details
Main Authors: Shen J, Yan H, Yang C, Lin H, Li F, Zhou J
Format: Article
Language:English
Published: Dove Medical Press 2023-04-01
Series:Breast Cancer: Targets and Therapy
Subjects:
Online Access:https://www.dovepress.com/validation-of-a-disease-free-survival-prediction-model-using-ube2c-and-peer-reviewed-fulltext-article-BCTT
_version_ 1827959594416078848
author Shen J
Yan H
Yang C
Lin H
Li F
Zhou J
author_facet Shen J
Yan H
Yang C
Lin H
Li F
Zhou J
author_sort Shen J
collection DOAJ
description Jun Shen,1,* Huanhuan Yan,1,* Congying Yang,2 Haiyue Lin,2 Fan Li,1 Jun Zhou1 1Department of Breast Surgery, The First People’s Hospital of Lianyungang, The First Affiliated Hospital of Kangda College of Nanjing Medical University, Lianyungang, Jiangsu, 222002, People’s Republic of China; 2Department of Pathology, The First People’s Hospital of Lianyungang, The First Affiliated Hospital of Kangda College of Nanjing Medical University, Lianyungang, Jiangsu, 222002, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jun Zhou, Department of Breast surgery, The First People’s Hospital of Lianyungang, The First Affiliated Hospital of Kangda College of Nanjing Medical University, No. 6 Zhenhua East Road, High-Tech Square, Lianyungang, Jiangsu Province, 222002, People’s Republic of China, Tel +86 18961326373, Email zhoujunzj91@126.comObjective: To explore the validation of a disease-free survival (DFS) model for predicting disease progression based on the combination of ubiquitin-conjugating enzyme E2 C (UBE2C) levels and clinical indicators in breast cancer patients.Methods: We enrolled 121 patients with breast cancer, collected their baseline characteristics and follow-up data, and analyzed the UBE2C levels in tumor tissues. We studied the relationship between UBE2C expression in tumor tissues and disease progression events of patients. We used the Kaplan-Meier method for identifying the disease-free survival rate of patients, and the multivariate Cox regression analysis to study the risk factors affecting the prognosis of patients. We sought to develop and validate a model for predicting disease progression.Results: We found that the level of expression of UBE2C could effectively distinguish the prognosis of patients. In the Receiver Operating Characteristic (ROC) curve analysis, the Area under the ROC Curve (AUC) = 0.826 (0.714– 0.938) indicating that high levels of UBE2C was a high-risk factor for poor prognosis. After evaluating different models using the ROC curve, Concordance index (C-index), calibration curve, Net Reclassification Index (NRI), Integrated Discrimination Improvement Index (IDI), and other methods, we finally developed a model for the expression of Tumor-Node (TN) staging using Ki-67 and UBE2C, which had an AUC=0.870, 95% CI of 0.786– 0.953. The traditional TN model had an AUC=0.717, and 95% CI of 0.581– 0.853. Decision Curve Analysis (DCA) and Clinical Impact Curve (CIC) analysis indicated that the model had good clinical benefits and it was relatively simple to use.Conclusion: We found that high levels of UBE2C was a high-risk factor for poor prognosis. The use of UBE2C in addition to other breast cancer-related indicators effectively predicted the possible disease progression, thus providing a reliable basis for clinical decision-making.Keywords: breast cancer, nomograms, prediction model, prognosis, UBE2C
first_indexed 2024-04-09T15:54:34Z
format Article
id doaj.art-d7daad4af4b64bf0aec196be59f56ca7
institution Directory Open Access Journal
issn 1179-1314
language English
last_indexed 2024-04-09T15:54:34Z
publishDate 2023-04-01
publisher Dove Medical Press
record_format Article
series Breast Cancer: Targets and Therapy
spelling doaj.art-d7daad4af4b64bf0aec196be59f56ca72023-04-25T18:55:19ZengDove Medical PressBreast Cancer: Targets and Therapy1179-13142023-04-01Volume 1529531083298Validation of a Disease-Free Survival Prediction Model Using UBE2C and Clinical Indicators in Breast Cancer PatientsShen JYan HYang CLin HLi FZhou JJun Shen,1,* Huanhuan Yan,1,* Congying Yang,2 Haiyue Lin,2 Fan Li,1 Jun Zhou1 1Department of Breast Surgery, The First People’s Hospital of Lianyungang, The First Affiliated Hospital of Kangda College of Nanjing Medical University, Lianyungang, Jiangsu, 222002, People’s Republic of China; 2Department of Pathology, The First People’s Hospital of Lianyungang, The First Affiliated Hospital of Kangda College of Nanjing Medical University, Lianyungang, Jiangsu, 222002, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jun Zhou, Department of Breast surgery, The First People’s Hospital of Lianyungang, The First Affiliated Hospital of Kangda College of Nanjing Medical University, No. 6 Zhenhua East Road, High-Tech Square, Lianyungang, Jiangsu Province, 222002, People’s Republic of China, Tel +86 18961326373, Email zhoujunzj91@126.comObjective: To explore the validation of a disease-free survival (DFS) model for predicting disease progression based on the combination of ubiquitin-conjugating enzyme E2 C (UBE2C) levels and clinical indicators in breast cancer patients.Methods: We enrolled 121 patients with breast cancer, collected their baseline characteristics and follow-up data, and analyzed the UBE2C levels in tumor tissues. We studied the relationship between UBE2C expression in tumor tissues and disease progression events of patients. We used the Kaplan-Meier method for identifying the disease-free survival rate of patients, and the multivariate Cox regression analysis to study the risk factors affecting the prognosis of patients. We sought to develop and validate a model for predicting disease progression.Results: We found that the level of expression of UBE2C could effectively distinguish the prognosis of patients. In the Receiver Operating Characteristic (ROC) curve analysis, the Area under the ROC Curve (AUC) = 0.826 (0.714– 0.938) indicating that high levels of UBE2C was a high-risk factor for poor prognosis. After evaluating different models using the ROC curve, Concordance index (C-index), calibration curve, Net Reclassification Index (NRI), Integrated Discrimination Improvement Index (IDI), and other methods, we finally developed a model for the expression of Tumor-Node (TN) staging using Ki-67 and UBE2C, which had an AUC=0.870, 95% CI of 0.786– 0.953. The traditional TN model had an AUC=0.717, and 95% CI of 0.581– 0.853. Decision Curve Analysis (DCA) and Clinical Impact Curve (CIC) analysis indicated that the model had good clinical benefits and it was relatively simple to use.Conclusion: We found that high levels of UBE2C was a high-risk factor for poor prognosis. The use of UBE2C in addition to other breast cancer-related indicators effectively predicted the possible disease progression, thus providing a reliable basis for clinical decision-making.Keywords: breast cancer, nomograms, prediction model, prognosis, UBE2Chttps://www.dovepress.com/validation-of-a-disease-free-survival-prediction-model-using-ube2c-and-peer-reviewed-fulltext-article-BCTTbreast cancernomogramsprediction modelprognosisube2c
spellingShingle Shen J
Yan H
Yang C
Lin H
Li F
Zhou J
Validation of a Disease-Free Survival Prediction Model Using UBE2C and Clinical Indicators in Breast Cancer Patients
Breast Cancer: Targets and Therapy
breast cancer
nomograms
prediction model
prognosis
ube2c
title Validation of a Disease-Free Survival Prediction Model Using UBE2C and Clinical Indicators in Breast Cancer Patients
title_full Validation of a Disease-Free Survival Prediction Model Using UBE2C and Clinical Indicators in Breast Cancer Patients
title_fullStr Validation of a Disease-Free Survival Prediction Model Using UBE2C and Clinical Indicators in Breast Cancer Patients
title_full_unstemmed Validation of a Disease-Free Survival Prediction Model Using UBE2C and Clinical Indicators in Breast Cancer Patients
title_short Validation of a Disease-Free Survival Prediction Model Using UBE2C and Clinical Indicators in Breast Cancer Patients
title_sort validation of a disease free survival prediction model using ube2c and clinical indicators in breast cancer patients
topic breast cancer
nomograms
prediction model
prognosis
ube2c
url https://www.dovepress.com/validation-of-a-disease-free-survival-prediction-model-using-ube2c-and-peer-reviewed-fulltext-article-BCTT
work_keys_str_mv AT shenj validationofadiseasefreesurvivalpredictionmodelusingube2candclinicalindicatorsinbreastcancerpatients
AT yanh validationofadiseasefreesurvivalpredictionmodelusingube2candclinicalindicatorsinbreastcancerpatients
AT yangc validationofadiseasefreesurvivalpredictionmodelusingube2candclinicalindicatorsinbreastcancerpatients
AT linh validationofadiseasefreesurvivalpredictionmodelusingube2candclinicalindicatorsinbreastcancerpatients
AT lif validationofadiseasefreesurvivalpredictionmodelusingube2candclinicalindicatorsinbreastcancerpatients
AT zhouj validationofadiseasefreesurvivalpredictionmodelusingube2candclinicalindicatorsinbreastcancerpatients